CHUNLI MEDICAL (01858) saw its stock price soar 9.24% in intraday trading, extending its post-earnings rally to nearly 25%. This significant uptick follows the company's recent release of impressive financial results for the first three quarters of the year, showcasing robust growth and a remarkable turnaround in profitability.

The medical device manufacturer reported a 48.75% year-on-year increase in revenue, reaching RMB 756 million for the first three quarters. More impressively, net profit surged by 213.21% to RMB 192 million. The third quarter performance was particularly strong, with revenue growing 109.51% year-on-year to RMB 268 million, and net profit attributable to shareholders turning positive at RMB 77.06 million, compared to a loss in the same period last year.

Analysts attribute CHUNLI MEDICAL's stellar performance to its successful international expansion strategy and increased sales of centralized procurement products. The company's overseas business has become a key revenue driver, with all its major product lines - hip, knee, and spine - passing CE annual system and surveillance audits. Furthermore, the recent FDA 510(K) clearance for its knee prosthesis system in the U.S. market demonstrates the company's international-leading technological capabilities and strengthens its global competitiveness. These developments, combined with ongoing overseas expansion efforts, position CHUNLI MEDICAL for continued rapid growth in its international business through 2025.